Clinical Trial Update: Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial evaluating whether circulating tumor DNA in blood can guide the use of immunotherapy after surgical removal of urothelial cancers of th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma of the Bladder
• Urothelial Carcinoma of the Renal Pelvis
• Urothelial Carcinoma of the Ureter
• Urothelial Carcinoma of the Urethra

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma | Phase 2, Phase 3 | Status: RECRUITING